EDITORIAL article
Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1651124
This article is part of the Research TopicHarnessing Nanotechnology for Cancer TreatmentView all 5 articles
Editorial: Harnessing Nanotechnology for Cancer Treatment
Provisionally accepted
- 1InterAmerican University of Puerto Rico, Puerto Rico, Puerto Rico
- 2Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
- 3University of Nebraska Medical Center, Omaha, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cancer is the second leading cause of death worldwide. According to the American Cancer 13 Society, it is projected that more than 35 million new cancer cases will occur by 2050 (1). 14Chemotherapy and radiation therapy are the most common treatments for this deadly disease. However, 15 they damage both healthy and cancer cells, leading to severe side effects (2,3). In the last years, 16 nanotechnology has gained significant interest as a promising tool to overcome these challenges. 17Therefore
Keywords: Cancer, Nanotechnology, bevacizumab, Targeted drug delivery systems, 11 Theranostics 12
Received: 20 Jun 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Alvarez-Berrios, Liu and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Merlis P. Alvarez-Berrios, InterAmerican University of Puerto Rico, Puerto Rico, Puerto Rico
Chuang Liu, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
Jingjing Sun, University of Nebraska Medical Center, Omaha, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.